Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway
Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which i...
Saved in:
| Published in | Molecular cancer Vol. 18; no. 1; pp. 84 - 15 |
|---|---|
| Main Authors | , , , , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
08.04.2019
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which is associated with several hematological malignancies. However, the functional relevance between aberrantly expressed lncRNAs and Bcr-Abl-mediated leukemia remains obscure.
LncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation. To study the functional relevance of novel imatinib-upregulated lncRNA (IUR) family in Abl-induced tumorigenesis, Abl-transformed cell survival and xenografted tumor growth in mice was evaluated. Primary bone marrow transformation and in vivo leukemia transplant using lncRNA-IUR knockdown (KD) transgenic mice were further conducted to corroborate the role of lncRNA-IUR in Abl-induced tumorigenesis. Transcriptome RNA-seq, Western blot, RNA pull down and RNA Immunoprecipitation (RIP) were employed to determine the mechanisms by which lncRNA-IUR-5 regulates Bcr-Abl-mediated tumorigenesis.
We identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis. Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. In contrast, reduced expression of lncRNA-IUR was observed in the peripheral blood lymphocytes derived from Bcr-Abl-positive acute lymphoblastic leukemia (ALL) patients compared to normal subjects. Knockdown of lncRNA-IUR remarkably promoted Abl-transformed leukemic cell survival and xenografted tumor growth in mice, whereas overexpression of lncRNA-IUR had opposite effects. Also, silencing murine lncRNA-IUR promoted Bcr-Abl-mediated primary bone marrow transformation and Abl-transformed leukemia cell survival in vivo. Besides, knockdown of murine lncRNA-IUR in transgenic mice provided a favorable microenvironment for development of Abl-mediated leukemia. Finally, we demonstrated that lncRNA-IUR-5 suppressed Bcr-Abl-mediated tumorigenesis by negatively regulating STAT5-mediated expression of CD71.
The results suggest that lncRNA-IUR may act as a critical tumor suppressor in Bcr-Abl-mediated tumorigenesis by suppressing the STAT5-CD71 pathway. This study provides new insights into functional involvement of lncRNAs in leukemogenesis. |
|---|---|
| AbstractList | Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which is associated with several hematological malignancies. However, the functional relevance between aberrantly expressed lncRNAs and Bcr-Abl-mediated leukemia remains obscure. LncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation. To study the functional relevance of novel imatinib-upregulated lncRNA (IUR) family in Abl-induced tumorigenesis, Abl-transformed cell survival and xenografted tumor growth in mice was evaluated. Primary bone marrow transformation and in vivo leukemia transplant using lncRNA-IUR knockdown (KD) transgenic mice were further conducted to corroborate the role of lncRNA-IUR in Abl-induced tumorigenesis. Transcriptome RNA-seq, Western blot, RNA pull down and RNA Immunoprecipitation (RIP) were employed to determine the mechanisms by which lncRNA-IUR-5 regulates Bcr-Abl-mediated tumorigenesis. We identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis. Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. In contrast, reduced expression of lncRNA-IUR was observed in the peripheral blood lymphocytes derived from Bcr-Abl-positive acute lymphoblastic leukemia (ALL) patients compared to normal subjects. Knockdown of lncRNA-IUR remarkably promoted Abl-transformed leukemic cell survival and xenografted tumor growth in mice, whereas overexpression of lncRNA-IUR had opposite effects. Also, silencing murine lncRNA-IUR promoted Bcr-Abl-mediated primary bone marrow transformation and Abl-transformed leukemia cell survival in vivo. Besides, knockdown of murine lncRNA-IUR in transgenic mice provided a favorable microenvironment for development of Abl-mediated leukemia. Finally, we demonstrated that lncRNA-IUR-5 suppressed Bcr-Abl-mediated tumorigenesis by negatively regulating STAT5-mediated expression of CD71. The results suggest that lncRNA-IUR may act as a critical tumor suppressor in Bcr-Abl-mediated tumorigenesis by suppressing the STAT5-CD71 pathway. This study provides new insights into functional involvement of lncRNAs in leukemogenesis. Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which is associated with several hematological malignancies. However, the functional relevance between aberrantly expressed lncRNAs and Bcr-Abl-mediated leukemia remains obscure. LncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation. To study the functional relevance of novel imatinib-upregulated lncRNA (IUR) family in Abl-induced tumorigenesis, Abl-transformed cell survival and xenografted tumor growth in mice was evaluated. Primary bone marrow transformation and in vivo leukemia transplant using lncRNA-IUR knockdown (KD) transgenic mice were further conducted to corroborate the role of lncRNA-IUR in Abl-induced tumorigenesis. Transcriptome RNA-seq, Western blot, RNA pull down and RNA Immunoprecipitation (RIP) were employed to determine the mechanisms by which lncRNA-IUR-5 regulates Bcr-Abl-mediated tumorigenesis. We identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis. Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. In contrast, reduced expression of lncRNA-IUR was observed in the peripheral blood lymphocytes derived from Bcr-Abl-positive acute lymphoblastic leukemia (ALL) patients compared to normal subjects. Knockdown of lncRNA-IUR remarkably promoted Abl-transformed leukemic cell survival and xenografted tumor growth in mice, whereas overexpression of lncRNA-IUR had opposite effects. Also, silencing murine lncRNA-IUR promoted Bcr-Abl-mediated primary bone marrow transformation and Abl-transformed leukemia cell survival in vivo. Besides, knockdown of murine lncRNA-IUR in transgenic mice provided a favorable microenvironment for development of Abl-mediated leukemia. Finally, we demonstrated that lncRNA-IUR-5 suppressed Bcr-Abl-mediated tumorigenesis by negatively regulating STAT5-mediated expression of CD71. The results suggest that lncRNA-IUR may act as a critical tumor suppressor in Bcr-Abl-mediated tumorigenesis by suppressing the STAT5-CD71 pathway. This study provides new insights into functional involvement of lncRNAs in leukemogenesis. Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which is associated with several hematological malignancies. However, the functional relevance between aberrantly expressed lncRNAs and Bcr-Abl-mediated leukemia remains obscure.BACKGROUNDLong noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which is associated with several hematological malignancies. However, the functional relevance between aberrantly expressed lncRNAs and Bcr-Abl-mediated leukemia remains obscure.LncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation. To study the functional relevance of novel imatinib-upregulated lncRNA (IUR) family in Abl-induced tumorigenesis, Abl-transformed cell survival and xenografted tumor growth in mice was evaluated. Primary bone marrow transformation and in vivo leukemia transplant using lncRNA-IUR knockdown (KD) transgenic mice were further conducted to corroborate the role of lncRNA-IUR in Abl-induced tumorigenesis. Transcriptome RNA-seq, Western blot, RNA pull down and RNA Immunoprecipitation (RIP) were employed to determine the mechanisms by which lncRNA-IUR-5 regulates Bcr-Abl-mediated tumorigenesis.METHODSLncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation. To study the functional relevance of novel imatinib-upregulated lncRNA (IUR) family in Abl-induced tumorigenesis, Abl-transformed cell survival and xenografted tumor growth in mice was evaluated. Primary bone marrow transformation and in vivo leukemia transplant using lncRNA-IUR knockdown (KD) transgenic mice were further conducted to corroborate the role of lncRNA-IUR in Abl-induced tumorigenesis. Transcriptome RNA-seq, Western blot, RNA pull down and RNA Immunoprecipitation (RIP) were employed to determine the mechanisms by which lncRNA-IUR-5 regulates Bcr-Abl-mediated tumorigenesis.We identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis. Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. In contrast, reduced expression of lncRNA-IUR was observed in the peripheral blood lymphocytes derived from Bcr-Abl-positive acute lymphoblastic leukemia (ALL) patients compared to normal subjects. Knockdown of lncRNA-IUR remarkably promoted Abl-transformed leukemic cell survival and xenografted tumor growth in mice, whereas overexpression of lncRNA-IUR had opposite effects. Also, silencing murine lncRNA-IUR promoted Bcr-Abl-mediated primary bone marrow transformation and Abl-transformed leukemia cell survival in vivo. Besides, knockdown of murine lncRNA-IUR in transgenic mice provided a favorable microenvironment for development of Abl-mediated leukemia. Finally, we demonstrated that lncRNA-IUR-5 suppressed Bcr-Abl-mediated tumorigenesis by negatively regulating STAT5-mediated expression of CD71.RESULTSWe identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis. Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. In contrast, reduced expression of lncRNA-IUR was observed in the peripheral blood lymphocytes derived from Bcr-Abl-positive acute lymphoblastic leukemia (ALL) patients compared to normal subjects. Knockdown of lncRNA-IUR remarkably promoted Abl-transformed leukemic cell survival and xenografted tumor growth in mice, whereas overexpression of lncRNA-IUR had opposite effects. Also, silencing murine lncRNA-IUR promoted Bcr-Abl-mediated primary bone marrow transformation and Abl-transformed leukemia cell survival in vivo. Besides, knockdown of murine lncRNA-IUR in transgenic mice provided a favorable microenvironment for development of Abl-mediated leukemia. Finally, we demonstrated that lncRNA-IUR-5 suppressed Bcr-Abl-mediated tumorigenesis by negatively regulating STAT5-mediated expression of CD71.The results suggest that lncRNA-IUR may act as a critical tumor suppressor in Bcr-Abl-mediated tumorigenesis by suppressing the STAT5-CD71 pathway. This study provides new insights into functional involvement of lncRNAs in leukemogenesis.CONCLUSIONSThe results suggest that lncRNA-IUR may act as a critical tumor suppressor in Bcr-Abl-mediated tumorigenesis by suppressing the STAT5-CD71 pathway. This study provides new insights into functional involvement of lncRNAs in leukemogenesis. Abstract Background Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which is associated with several hematological malignancies. However, the functional relevance between aberrantly expressed lncRNAs and Bcr-Abl-mediated leukemia remains obscure. Methods LncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation. To study the functional relevance of novel imatinib-upregulated lncRNA (IUR) family in Abl-induced tumorigenesis, Abl-transformed cell survival and xenografted tumor growth in mice was evaluated. Primary bone marrow transformation and in vivo leukemia transplant using lncRNA-IUR knockdown (KD) transgenic mice were further conducted to corroborate the role of lncRNA-IUR in Abl-induced tumorigenesis. Transcriptome RNA-seq, Western blot, RNA pull down and RNA Immunoprecipitation (RIP) were employed to determine the mechanisms by which lncRNA-IUR-5 regulates Bcr-Abl-mediated tumorigenesis. Results We identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis. Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. In contrast, reduced expression of lncRNA-IUR was observed in the peripheral blood lymphocytes derived from Bcr-Abl-positive acute lymphoblastic leukemia (ALL) patients compared to normal subjects. Knockdown of lncRNA-IUR remarkably promoted Abl-transformed leukemic cell survival and xenografted tumor growth in mice, whereas overexpression of lncRNA-IUR had opposite effects. Also, silencing murine lncRNA-IUR promoted Bcr-Abl-mediated primary bone marrow transformation and Abl-transformed leukemia cell survival in vivo. Besides, knockdown of murine lncRNA-IUR in transgenic mice provided a favorable microenvironment for development of Abl-mediated leukemia. Finally, we demonstrated that lncRNA-IUR-5 suppressed Bcr-Abl-mediated tumorigenesis by negatively regulating STAT5-mediated expression of CD71. Conclusions The results suggest that lncRNA-IUR may act as a critical tumor suppressor in Bcr-Abl-mediated tumorigenesis by suppressing the STAT5-CD71 pathway. This study provides new insights into functional involvement of lncRNAs in leukemogenesis. Background Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which is associated with several hematological malignancies. However, the functional relevance between aberrantly expressed lncRNAs and Bcr-Abl-mediated leukemia remains obscure. Methods LncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation. To study the functional relevance of novel imatinib-upregulated lncRNA (IUR) family in Abl-induced tumorigenesis, Abl-transformed cell survival and xenografted tumor growth in mice was evaluated. Primary bone marrow transformation and in vivo leukemia transplant using lncRNA-IUR knockdown (KD) transgenic mice were further conducted to corroborate the role of lncRNA-IUR in Abl-induced tumorigenesis. Transcriptome RNA-seq, Western blot, RNA pull down and RNA Immunoprecipitation (RIP) were employed to determine the mechanisms by which lncRNA-IUR-5 regulates Bcr-Abl-mediated tumorigenesis. Results We identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis. Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. In contrast, reduced expression of lncRNA-IUR was observed in the peripheral blood lymphocytes derived from Bcr-Abl-positive acute lymphoblastic leukemia (ALL) patients compared to normal subjects. Knockdown of lncRNA-IUR remarkably promoted Abl-transformed leukemic cell survival and xenografted tumor growth in mice, whereas overexpression of lncRNA-IUR had opposite effects. Also, silencing murine lncRNA-IUR promoted Bcr-Abl-mediated primary bone marrow transformation and Abl-transformed leukemia cell survival in vivo. Besides, knockdown of murine lncRNA-IUR in transgenic mice provided a favorable microenvironment for development of Abl-mediated leukemia. Finally, we demonstrated that lncRNA-IUR-5 suppressed Bcr-Abl-mediated tumorigenesis by negatively regulating STAT5-mediated expression of CD71. Conclusions The results suggest that lncRNA-IUR may act as a critical tumor suppressor in Bcr-Abl-mediated tumorigenesis by suppressing the STAT5-CD71 pathway. This study provides new insights into functional involvement of lncRNAs in leukemogenesis. Background Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in diverse human diseases including cancer. A reciprocal translocation between chromosome 9 and 22 generates the chimeric Bcr-Abl oncogene, which is associated with several hematological malignancies. However, the functional relevance between aberrantly expressed lncRNAs and Bcr-Abl-mediated leukemia remains obscure. Methods LncRNA cDNA microarray was used to identify novel lncRNAs involved in Bcr-Abl-mediated cellular transformation. To study the functional relevance of novel imatinib-upregulated lncRNA (IUR) family in Abl-induced tumorigenesis, Abl-transformed cell survival and xenografted tumor growth in mice was evaluated. Primary bone marrow transformation and in vivo leukemia transplant using lncRNA-IUR knockdown (KD) transgenic mice were further conducted to corroborate the role of lncRNA-IUR in Abl-induced tumorigenesis. Transcriptome RNA-seq, Western blot, RNA pull down and RNA Immunoprecipitation (RIP) were employed to determine the mechanisms by which lncRNA-IUR-5 regulates Bcr-Abl-mediated tumorigenesis. Results We identified a conserved lncRNA-IUR family as a key negative regulator of Bcr-Abl-induced tumorigenesis. Increased expression of lncRNA-IUR was detected in both human and mouse Abl-transformed cells upon imatinib treatment. In contrast, reduced expression of lncRNA-IUR was observed in the peripheral blood lymphocytes derived from Bcr-Abl-positive acute lymphoblastic leukemia (ALL) patients compared to normal subjects. Knockdown of lncRNA-IUR remarkably promoted Abl-transformed leukemic cell survival and xenografted tumor growth in mice, whereas overexpression of lncRNA-IUR had opposite effects. Also, silencing murine lncRNA-IUR promoted Bcr-Abl-mediated primary bone marrow transformation and Abl-transformed leukemia cell survival in vivo. Besides, knockdown of murine lncRNA-IUR in transgenic mice provided a favorable microenvironment for development of Abl-mediated leukemia. Finally, we demonstrated that lncRNA-IUR-5 suppressed Bcr-Abl-mediated tumorigenesis by negatively regulating STAT5-mediated expression of CD71. Conclusions The results suggest that lncRNA-IUR may act as a critical tumor suppressor in Bcr-Abl-mediated tumorigenesis by suppressing the STAT5-CD71 pathway. This study provides new insights into functional involvement of lncRNAs in leukemogenesis. Keywords: LncRNA, Imatinib, Bcr-Abl, Cellular transformation, Leukemia |
| ArticleNumber | 84 |
| Audience | Academic |
| Author | Feng, Riyue Yang, Jianling Zhang, Lianfeng Chen, Ji-Long Wang, Xuefei Sun, Liping Huang, Shile Chen, Ke Guo, Guijie Liao, Yuan |
| Author_xml | – sequence: 1 givenname: Xuefei surname: Wang fullname: Wang, Xuefei – sequence: 2 givenname: Jianling surname: Yang fullname: Yang, Jianling – sequence: 3 givenname: Guijie surname: Guo fullname: Guo, Guijie – sequence: 4 givenname: Riyue surname: Feng fullname: Feng, Riyue – sequence: 5 givenname: Ke surname: Chen fullname: Chen, Ke – sequence: 6 givenname: Yuan surname: Liao fullname: Liao, Yuan – sequence: 7 givenname: Lianfeng surname: Zhang fullname: Zhang, Lianfeng – sequence: 8 givenname: Liping surname: Sun fullname: Sun, Liping – sequence: 9 givenname: Shile surname: Huang fullname: Huang, Shile – sequence: 10 givenname: Ji-Long surname: Chen fullname: Chen, Ji-Long |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/30961617$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kktv1DAUhSNURB_wA9igSGzYuPj6GW-QhuE1UlWkMl1bjuNkPMrEg50U9d_j6ZTSqRDywtb1d47vtc5pcTSEwRXFa8DnAJV4n4AoRhEGhQADRfRZcQJMCsS4qo4enY-L05TWGIOsJHtRHFOsBAiQJ0V9GW5cX_aDvbqcocX1VZmm7Ta6lFwqP9qIZnWP_NBM1jXlOG1C9J0bXPKpHFcxTN2qjK6bejP6MJShLX8sZ0uO5p8klFszrn6Z25fF89b0yb2638-K6y-fl_Nv6OL718V8doEsF3hErRAVVERi4lTNGgOMO2KIxZiyFnNhrGBEspbbmimWQQdG4EpxyTFT3NKzYrH3bYJZ6230GxNvdTBe3xVC7LSJo7e906oxhivTCqgqxgypKcVWWtq24BqoVfb6sPfaTvXGNdYNYzT9genhzeBXugs3WjDOhGDZ4N29QQw_J5dGvfHJur43gwtT0oRgQQjnFWT07RN0HaY45K_KFACnUhD2l-pMHsAPbcjv2p2pnvGKggSGd32f_4PKq3Ebb3N6Wp_rB4I3jwd9mPBPQjIAe8DGkFJ07QMCWO9SqPcp1DmFepdCTbNGPtFYP94lJHfj-_8ofwMozd0f |
| CitedBy_id | crossref_primary_10_1016_j_prp_2024_155314 crossref_primary_10_3389_fcell_2022_857612 crossref_primary_10_1155_2022_9471558 crossref_primary_10_1097_CMR_0000000000000803 crossref_primary_10_1186_s12859_021_04548_z crossref_primary_10_3390_ijms20205118 crossref_primary_10_1016_j_molimm_2021_10_016 crossref_primary_10_1186_s12943_022_01539_3 crossref_primary_10_1080_15384101_2020_1783481 crossref_primary_10_1152_physiolgenomics_00062_2019 crossref_primary_10_3389_fonc_2023_1276715 crossref_primary_10_1016_j_tibs_2020_10_003 crossref_primary_10_3390_ijms23084442 crossref_primary_10_1016_j_critrevonc_2024_104290 crossref_primary_10_2147_CMAR_S236188 crossref_primary_10_1016_j_omtn_2020_07_005 crossref_primary_10_3389_fcell_2019_00350 crossref_primary_10_3390_ncrna9040044 crossref_primary_10_1016_j_prp_2023_154657 crossref_primary_10_1016_j_bbrc_2019_04_203 crossref_primary_10_1186_s12943_020_1132_x crossref_primary_10_1007_s10388_020_00724_x crossref_primary_10_1080_13813455_2020_1799018 crossref_primary_10_1186_s12943_020_01225_2 crossref_primary_10_18632_aging_203116 crossref_primary_10_1016_j_gene_2020_144405 crossref_primary_10_1089_cbr_2019_3436 crossref_primary_10_1016_j_bcp_2022_114970 crossref_primary_10_1155_2021_6696198 crossref_primary_10_1186_s12864_022_08880_3 crossref_primary_10_1186_s12943_021_01478_5 crossref_primary_10_3389_fcell_2021_669363 crossref_primary_10_3389_fmolb_2021_632837 crossref_primary_10_1007_s12033_022_00455_7 |
| Cites_doi | 10.1016/S0145-2126(01)00197-7 10.1038/sj.leu.2403241 10.1016/j.tig.2014.06.001 10.1002/ijc.30546 10.1016/j.molcel.2014.04.025 10.1038/nature17161 10.1038/onc.2014.131 10.1038/leu.2008.26 10.1182/blood-2008-02-138339 10.1038/onc.2010.149 10.1186/s12943-018-0920-z 10.1056/NEJM200104053441401 10.1002/hep.30098 10.1186/s12943-016-0535-1 10.1016/j.neo.2018.09.002 10.1016/j.clim.2006.06.010 10.1038/sj.onc.1203484 10.1016/j.cell.2014.08.038 10.1016/j.tcb.2011.04.001 10.1093/bfgp/elv059 10.1038/leu.2013.192 10.1186/1476-4598-12-133 10.1038/ncomms10221 10.1186/s12943-016-0545-z 10.1016/S0140-6736(13)62120-0 10.3390/ijms16023251 10.1016/j.clim.2006.06.006 10.1016/j.devcel.2010.03.008 10.4149/neo_2016_519 10.1596/neo.12230 10.1016/j.febslet.2014.03.038 10.1002/cncr.22881 10.1038/nature08975 10.1056/NEJMoa011573 10.1158/0008-5472.CAN-12-4277 10.1016/j.chom.2014.10.001 10.1002/cncr.28882 10.1016/j.cell.2007.05.022 10.1038/nrd4018 10.1038/nrc.2016.140 10.1182/blood-2007-04-083808 10.1016/j.bbagen.2011.07.016 10.1182/blood-2014-07-585943 10.1016/j.ccell.2016.03.010 |
| ContentType | Journal Article |
| Copyright | COPYRIGHT 2019 BioMed Central Ltd. 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. The Author(s). 2019 |
| Copyright_xml | – notice: COPYRIGHT 2019 BioMed Central Ltd. – notice: 2019. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License. – notice: The Author(s). 2019 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7TO 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH H94 K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA |
| DOI | 10.1186/s12943-019-1013-3 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials Local Electronic Collection Information ProQuest Central ProQuest One Community College ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) Medical Database ProQuest Central Premium ProQuest One Academic Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database Oncogenes and Growth Factors Abstracts ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection AIDS and Cancer Research Abstracts ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic Publicly Available Content Database |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1476-4598 |
| EndPage | 15 |
| ExternalDocumentID | oai_doaj_org_article_9daa59af618844a2b330c7c3ff1ed1b9 PMC6454664 A583171409 30961617 10_1186_s12943_019_1013_3 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GeographicLocations | Beijing China United States--US China |
| GeographicLocations_xml | – name: China – name: Beijing China – name: United States--US |
| GrantInformation_xml | – fundername: ; grantid: 91640101; U1805231; 81472611 – fundername: ; grantid: H2016206474 – fundername: ; grantid: 2015CB910502 |
| GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EJD EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR INH INR ITC KQ8 M1P M48 M~E O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PQQKQ PROAC PSQYO PZZ RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB -A0 3V. ACRMQ ADINQ C24 CGR CUY CVF ECM EIF FRP NPM PMFND 7TO 7XB 8FK AZQEC DWQXO H94 K9. PJZUB PKEHL PPXIY PQEST PQUKI PRINS 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c560t-f668182702e9b4da145e2a2c0034f056ac64274f5cb494827e1a60895750495c3 |
| IEDL.DBID | M48 |
| ISSN | 1476-4598 |
| IngestDate | Wed Aug 27 01:31:42 EDT 2025 Thu Aug 21 14:17:43 EDT 2025 Fri Jul 11 07:08:20 EDT 2025 Fri Jul 25 20:03:49 EDT 2025 Tue Jun 17 21:37:33 EDT 2025 Tue Jun 10 20:47:25 EDT 2025 Thu Jan 02 22:58:35 EST 2025 Tue Jul 01 01:01:16 EDT 2025 Thu Apr 24 22:55:37 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | LncRNA Bcr-Abl Imatinib Cellular transformation Leukemia |
| Language | English |
| License | Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c560t-f668182702e9b4da145e2a2c0034f056ac64274f5cb494827e1a60895750495c3 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
| OpenAccessLink | http://journals.scholarsportal.info/openUrl.xqy?doi=10.1186/s12943-019-1013-3 |
| PMID | 30961617 |
| PQID | 2211537624 |
| PQPubID | 42702 |
| PageCount | 15 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9daa59af618844a2b330c7c3ff1ed1b9 pubmedcentral_primary_oai_pubmedcentral_nih_gov_6454664 proquest_miscellaneous_2206225581 proquest_journals_2211537624 gale_infotracmisc_A583171409 gale_infotracacademiconefile_A583171409 pubmed_primary_30961617 crossref_primary_10_1186_s12943_019_1013_3 crossref_citationtrail_10_1186_s12943_019_1013_3 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2019-04-08 |
| PublicationDateYYYYMMDD | 2019-04-08 |
| PublicationDate_xml | – month: 04 year: 2019 text: 2019-04-08 day: 08 |
| PublicationDecade | 2010 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Molecular cancer |
| PublicationTitleAlternate | Mol Cancer |
| PublicationYear | 2019 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | J Zhou (1013_CR22) 2015; 6 NN Danial (1013_CR33) 2000; 19 AT Byrne (1013_CR44) 2017; 17 AM Schmitt (1013_CR10) 2016; 29 Z Peng (1013_CR12) 2018; 17 RA Gupta (1013_CR14) 2010; 464 J Ouyang (1013_CR21) 2014; 16 G Guo (1013_CR18) 2015; 34 KA Dorritie (1013_CR29) 2014; 28 KW Vance (1013_CR38) 2014; 30 H Stegeman (1013_CR31) 2013; 12 MA Kerenyi (1013_CR28) 2008; 112 TR Daniels (1013_CR24) 2006; 121 G Guo (1013_CR5) 2010; 29 O Wapinski (1013_CR11) 2011; 21 N Liu (1013_CR23) 2018; 68 LS Steelman (1013_CR34) 2004; 18 S Serghiou (1013_CR36) 2016; 15 CC Chen (1013_CR43) 2010; 18 TR Daniels (1013_CR25) 2012; 1820 C Wahlestedt (1013_CR35) 2013; 12 JF Apperley (1013_CR1) 2015; 385 C Jiang (1013_CR16) 2016; 15 LS Steelman (1013_CR32) 2008; 22 JL Chen (1013_CR3) 2008; 111 S Chandra Gupta (1013_CR17) 2017; 140 R Feng (1013_CR37) 2018; 20 J Yang (1013_CR2) 2013; 73 TR Daniels (1013_CR26) 2006; 121 BJ Druker (1013_CR8) 2001; 344 M Peng (1013_CR42) 2014; 159 X Qiu (1013_CR4) 2012; 14 VE Villegas (1013_CR41) 2015; 16 Y Shao (1013_CR13) 2014; 120 H Kantarjian (1013_CR9) 2002; 346 N Dimitrova (1013_CR40) 2014; 54 B Wu (1013_CR27) 2016; 63 PP Piccaluga (1013_CR6) 2007; 110 JL Rinn (1013_CR39) 2007; 129 AS Advani (1013_CR7) 2002; 26 P Valent (1013_CR30) 2014; 124 E Leucci (1013_CR15) 2016; 531 X Wang (1013_CR20) 2016; 15 G Guo (1013_CR19) 2014; 588 |
| References_xml | – volume: 26 start-page: 713 year: 2002 ident: 1013_CR7 publication-title: Leuk Res doi: 10.1016/S0145-2126(01)00197-7 – volume: 18 start-page: 189 year: 2004 ident: 1013_CR34 publication-title: Leukemia. doi: 10.1038/sj.leu.2403241 – volume: 30 start-page: 348 year: 2014 ident: 1013_CR38 publication-title: Trends Genet doi: 10.1016/j.tig.2014.06.001 – volume: 140 start-page: 1955 year: 2017 ident: 1013_CR17 publication-title: Int J Cancer doi: 10.1002/ijc.30546 – volume: 54 start-page: 777 year: 2014 ident: 1013_CR40 publication-title: Mol Cell doi: 10.1016/j.molcel.2014.04.025 – volume: 531 start-page: 518 year: 2016 ident: 1013_CR15 publication-title: Nature. doi: 10.1038/nature17161 – volume: 34 start-page: 1768 year: 2015 ident: 1013_CR18 publication-title: Oncogene. doi: 10.1038/onc.2014.131 – volume: 22 start-page: 686 year: 2008 ident: 1013_CR32 publication-title: Leukemia. doi: 10.1038/leu.2008.26 – volume: 112 start-page: 3878 year: 2008 ident: 1013_CR28 publication-title: Blood. doi: 10.1182/blood-2008-02-138339 – volume: 29 start-page: 3845 year: 2010 ident: 1013_CR5 publication-title: Oncogene. doi: 10.1038/onc.2010.149 – volume: 17 start-page: 167 year: 2018 ident: 1013_CR12 publication-title: Mol Cancer doi: 10.1186/s12943-018-0920-z – volume: 344 start-page: 1031 year: 2001 ident: 1013_CR8 publication-title: N Engl J Med doi: 10.1056/NEJM200104053441401 – volume: 68 start-page: 2130 year: 2018 ident: 1013_CR23 publication-title: Hepatology. doi: 10.1002/hep.30098 – volume: 15 start-page: 50 year: 2016 ident: 1013_CR36 publication-title: Mol Cancer doi: 10.1186/s12943-016-0535-1 – volume: 20 start-page: 1095 year: 2018 ident: 1013_CR37 publication-title: Neoplasia. doi: 10.1016/j.neo.2018.09.002 – volume: 121 start-page: 144 year: 2006 ident: 1013_CR24 publication-title: Clin Immunol doi: 10.1016/j.clim.2006.06.010 – volume: 19 start-page: 2523 year: 2000 ident: 1013_CR33 publication-title: Oncogene. doi: 10.1038/sj.onc.1203484 – volume: 159 start-page: 122 year: 2014 ident: 1013_CR42 publication-title: Cell. doi: 10.1016/j.cell.2014.08.038 – volume: 21 start-page: 354 year: 2011 ident: 1013_CR11 publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2011.04.001 – volume: 15 start-page: 239 year: 2016 ident: 1013_CR20 publication-title: Brief Funct Genomics doi: 10.1093/bfgp/elv059 – volume: 28 start-page: 248 year: 2014 ident: 1013_CR29 publication-title: Leukemia. doi: 10.1038/leu.2013.192 – volume: 12 start-page: 133 year: 2013 ident: 1013_CR31 publication-title: Mol Cancer doi: 10.1186/1476-4598-12-133 – volume: 6 year: 2015 ident: 1013_CR22 publication-title: Nat Commun doi: 10.1038/ncomms10221 – volume: 15 start-page: 62 year: 2016 ident: 1013_CR16 publication-title: Mol Cancer doi: 10.1186/s12943-016-0545-z – volume: 385 start-page: 1447 year: 2015 ident: 1013_CR1 publication-title: Lancet. doi: 10.1016/S0140-6736(13)62120-0 – volume: 16 start-page: 3251 year: 2015 ident: 1013_CR41 publication-title: Int J Mol Sci doi: 10.3390/ijms16023251 – volume: 121 start-page: 159 year: 2006 ident: 1013_CR26 publication-title: Clin Immunol doi: 10.1016/j.clim.2006.06.006 – volume: 18 start-page: 592 year: 2010 ident: 1013_CR43 publication-title: Dev Cell doi: 10.1016/j.devcel.2010.03.008 – volume: 63 start-page: 809 year: 2016 ident: 1013_CR27 publication-title: Neoplasma. doi: 10.4149/neo_2016_519 – volume: 14 start-page: 547 year: 2012 ident: 1013_CR4 publication-title: Neoplasia. doi: 10.1596/neo.12230 – volume: 588 start-page: 1780 year: 2014 ident: 1013_CR19 publication-title: FEBS Lett doi: 10.1016/j.febslet.2014.03.038 – volume: 110 start-page: 1178 year: 2007 ident: 1013_CR6 publication-title: Cancer. doi: 10.1002/cncr.22881 – volume: 464 start-page: 1071 year: 2010 ident: 1013_CR14 publication-title: Nature. doi: 10.1038/nature08975 – volume: 346 start-page: 645 year: 2002 ident: 1013_CR9 publication-title: N Engl J Med doi: 10.1056/NEJMoa011573 – volume: 73 start-page: 4898 year: 2013 ident: 1013_CR2 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-4277 – volume: 16 start-page: 616 year: 2014 ident: 1013_CR21 publication-title: Cell Host Microbe doi: 10.1016/j.chom.2014.10.001 – volume: 120 start-page: 3320 year: 2014 ident: 1013_CR13 publication-title: Cancer. doi: 10.1002/cncr.28882 – volume: 129 start-page: 1311 year: 2007 ident: 1013_CR39 publication-title: Cell. doi: 10.1016/j.cell.2007.05.022 – volume: 12 start-page: 433 year: 2013 ident: 1013_CR35 publication-title: Nat Rev Drug Discov doi: 10.1038/nrd4018 – volume: 17 start-page: 254 year: 2017 ident: 1013_CR44 publication-title: Nat Rev Cancer doi: 10.1038/nrc.2016.140 – volume: 111 start-page: 1677 year: 2008 ident: 1013_CR3 publication-title: Blood. doi: 10.1182/blood-2007-04-083808 – volume: 1820 start-page: 291 year: 2012 ident: 1013_CR25 publication-title: Biochim Biophys Acta doi: 10.1016/j.bbagen.2011.07.016 – volume: 124 start-page: 1386 year: 2014 ident: 1013_CR30 publication-title: Blood. doi: 10.1182/blood-2014-07-585943 – volume: 29 start-page: 452 year: 2016 ident: 1013_CR10 publication-title: Cancer Cell doi: 10.1016/j.ccell.2016.03.010 |
| SSID | ssj0017874 |
| Score | 2.429144 |
| Snippet | Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in... Background Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly... Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly expressed in... Background Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be aberrantly... Abstract Background Long noncoding RNAs (lncRNAs), defined as the transcripts longer than 200 nt without protein-coding capacity, have been found to be... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source |
| StartPage | 84 |
| SubjectTerms | Acute lymphoblastic leukemia Acute lymphocytic leukemia Adolescent Adult Animals Antigens, CD - genetics Antigens, CD - metabolism Antineoplastic agents Antineoplastic Agents - pharmacology Apoptosis Bcr-Abl BCR-ABL protein Bone marrow Bone marrow transplantation Bosutinib Cancer Carcinogenesis - genetics Carcinogenesis - metabolism Carcinogenesis - pathology Cell cycle Cell Line, Tumor Cell survival Cellular transformation Child, Preschool Chromosome 9 Dasatinib DNA microarrays Female Fusion protein Fusion Proteins, bcr-abl - genetics Fusion Proteins, bcr-abl - metabolism Gene expression Gene Expression Regulation, Neoplastic Genetic aspects Genetic engineering Genetic transformation Genomes Humans Imatinib Imatinib Mesylate - pharmacology Immunoprecipitation Kinases Leukemia Leukemia, Myelogenous, Chronic, BCR-ABL Positive - drug therapy Leukemia, Myelogenous, Chronic, BCR-ABL Positive - genetics Leukemia, Myelogenous, Chronic, BCR-ABL Positive - metabolism Leukemia, Myelogenous, Chronic, BCR-ABL Positive - pathology Leukemogenesis LncRNA Lymphatic leukemia Lymphocytes Lymphocytic leukemia Male Mice Mice, Nude Nilotinib Novels Oligoribonucleotides - genetics Oligoribonucleotides - metabolism Peripheral blood Ponatinib Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - drug therapy Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - metabolism Precursor T-Cell Lymphoblastic Leukemia-Lymphoma - pathology Proteins Receptors, Transferrin - genetics Receptors, Transferrin - metabolism Ribonucleic acid RNA RNA, Long Noncoding - agonists RNA, Long Noncoding - antagonists & inhibitors RNA, Long Noncoding - genetics RNA, Long Noncoding - metabolism RNA, Small Interfering - genetics RNA, Small Interfering - metabolism Signal Transduction Stat5 protein STAT5 Transcription Factor - genetics STAT5 Transcription Factor - metabolism Systematic review Targeted cancer therapy Transformed cells Transgenic animals Transgenic mice Tumor suppressor genes Tumorigenesis Tumors Xenograft Model Antitumor Assays Xenografts |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1baxQxFA5SUHwRrbexVSIIghC6mVwm8zitlip0H-ou9C0kmQwW1tmys2vpv_ecmeyyg6Avvk4SmOTcycn3EfKhEdznQpQMQmtk0ivwg3lsGI-F4SIYr3u4psupvpjLb9fqeo_qC3vCBnjg4eBOyto5VbpGc2OkdLmHAjwUQTQNjzX3_dM9iHnbYirdH4AaynSHyY0-6SCqSewbKsHtcMHEKAr1YP1_uuS9mDTul9wLQOdPyZOUOdJq-ONn5EFsD8nDgUvy_pA8uky35M-Jny5_xQVdtOFqWrGv8yvabW77htfY0dOwYpVfMKjFQao1XW9-IjkWurybjibaHroaKOpBaHTZ0O-zaqbY2eeCU2QwvnP3L8j8_Mvs7IIlLgUWIKdZs0ZrCM34-CyWXtaOSxVzlwfEp2kgCXIBCpFCNip4BIzJi8idnphSIfx7qYJ4SQ7aZRtfE-q8G4DiYJWslXe6hLyhkNHk3jtuMjLZnq0NCWgc-S4Wti84jLaDOCyIAzvMhBUZ-bRbcjugbPxt8ikKbDcRAbL7D6A2NqmN_ZfaZOQjituiGcPPBZdeI8AWERDLVsoI5IafwMzj0UwwvzAe3iqMTebf2RzKasTJyWVG3u-GcSW2tLVxucE5Ew3OVBmekVeDfu22JJCIB3LLjBQjzRvteTzS3vzowcERoU1r-eZ_HNIReZyjzWCjkjkmB-vVJr6FHGzt3_Xm9huFxSp2 priority: 102 providerName: Directory of Open Access Journals – databaseName: Health & Medical Collection dbid: 7X7 link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZgCLQXBOMWGMhISEhI1ur4EucJdYNpIK0Po5X6FtmOMyaVpGta0P495yRuWYS01_pYinvu8cn3EfKhEtylQuQMUmtg0imIg2moGA-Z4cIbpzu4pvOJPpvJ73M1jy_c2jhWuY2JXaAuG4_vyI9S6FQQeiSVn5fXDFmj8HY1UmjcJw8QugytOpvvGi4OxijjTSY3-qiF3CZxeiiH4MMFE4Nc1EH2_x-Yb2Wm4dTkrTR0-oQ8jvUjHfcKf0ruhfqAPOwZJW8OyKPzeFf-jLhJ8zss6KL2F5Mx-za7oO1m2Y29hpYe-xUbuwWDjhx0W9L15hceFgPfVUsjeQ9d9UT1oDraVPTHdDxV7ORLxinyGP-xN8_J7PTr9OSMRUYF5qGyWbNKa0jQ-AlayJ0sLZcqpDb1iFJTQSlkPbQjmayUdwgbk2aBWz0yuUIQ-Fx58YLs1U0dXhFqne3h4mCXLJWzOofqIZPBpM5ZbhIy2v63hY9w48h6sSi6tsPooldHAerAOTNRiIR82m1Z9lgbdwkfo8J2ggiT3f3QrC6L6HVFXlqrcltpboyUNnVCjHzmRVXxUHKXJ-QjqrtAZ4aH8zZ-kwBHRFisYqyMQIb4EUgeDiTBCf1weWswRQwCbfHPZBPyfreMO3GwrQ7NBmVGGkKqMjwhL3v72h1JIB0PVJgJyQaWNzjzcKW--tlBhCNOm9by9d2P9Ybsp-gNOIhkDsneerUJb6HGWrt3nSP9BfGEIRQ priority: 102 providerName: ProQuest |
| Title | Novel lncRNA-IUR suppresses Bcr-Abl-induced tumorigenesis through regulation of STAT5-CD71 pathway |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/30961617 https://www.proquest.com/docview/2211537624 https://www.proquest.com/docview/2206225581 https://pubmed.ncbi.nlm.nih.gov/PMC6454664 https://doaj.org/article/9daa59af618844a2b330c7c3ff1ed1b9 |
| Volume | 18 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3ti9MwGA_3guIX0VPP6jkiCIJQXZo0TT-IdOcd52BDdhvsW0jSVA9md-5F3X_v87TdvOLhJz8VlifQ5HnN8vT3I-RVwZmNOE9DSK0-FDaGOBj5ImQ-UYw7ZWUF1zQYyouJ6E_j6R7Z0ls1G7i89WiHfFKTxeztr--bD-Dw7yuHV_LdEnKWwK6gFIIK4yHfJ4eQmBIkNBiIP5cKYJuiudi8dVorNVUI_n_H6RuJqt1EeSMrnT8g95tykma1_h-SPV8ekTs1weTmiNwdNFfnj4gdzn_4GZ2VbjTMwk-TEV2ur6suWL-kPbcIMzsL4YAOqs7pav0NGbMwDl4tacPlQxc1bz1oks4LejnOxnF4-jFhFGmNf5rNYzI5PxufXoQNwULooNBZhYWUkK_xizSfWpEbJmIfmcghaE0BlZFxcDpJRBE7iygyUeKZkV2VxogJn8aOPyEH5bz0Twk11tTocTBL5LE1MoViIhFeRdYapgLS3e6tdg36OJJgzHR1ClFS1-rQoA5sO-OaB-TNbsp1Db3xL-EeKmwniKjZ1Q_zxRfdOKFOc2Pi1BSSKSWEiSznXZc4XhTM58ymAXmN6tZobfByzjSfKMASESVLZ7HiSBjfBcmTliT4pGsPbw1Gb01aR3DWRvCcSATk5W4YZ2KfW-nna5TpSoiwsWIBOa7ta7ckjuw8UHAGJGlZXmvN7ZHy6muFGI6wbVKKZ_9jk56TexH6DHYvqRNysFqs_QsozFa2Q_aTadIhh1nWv-zDs3c2_DzqVH9zdCpX_A1dajaC |
| linkProvider | Scholars Portal |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1bb9MwFLbGEJcXBOMWGBAkEBJStDh2HOcBoW5jatnah9FKfTO244xKJSm9MPVP8Rs5J0nLIqS97TW2o9jn6vj4-wh5lzNqIsbSAEKrC7iJwQ9GLg-oSyRlVhpRwTX1B6I74l_H8XiH_NnchcGyyo1PrBx1Vlr8R34QwU4FoUci_nn2K0DWKDxd3VBo1Gpx6taXsGVbfOodg3zfR9HJl-FRN2hYBQIL0X0Z5EJAkMJrWC41PNOUxy7SkUWklhzSAW0hJU94HluD0ClR4qgWoUxjBEJPY8vgvbfIbQi8IW72kvF2g0dB-XlzckqlOFhALOVYrZSCs6MsYK3YV1EE_B8IrkTCdpXmlbB38pA8aPJVv1Mr2COy44o9cqdmsFzvkbv95mz-MTGD8reb-tPCng86QW907i9Ws6rM1i38QzsPOmYaTIoMdCnzl6ufuLjoaCcLvyEL8ufuomET88vc_zbsDOPg6DihPvImX-r1EzK6kbV-SnaLsnDPia-NruHpYBTPYqNFCtlKwp2MjNFUeiTcrK2yDbw5smxMVbXNkULV4lAgDqxrY4p55ON2yKzG9riu8yEKbNsRYbmrB-X8QjVWrtJM6zjVuaBScq4jw1hoE8vynLqMmtQjH1DcCp0HfJzVzR0ImCLCcKlOLBky0ofQc7_VE4zetps3CqMap7NQ_0zEI2-3zTgSC-kKV66wTyjAhceSeuRZrV_bKTGk_4GM1iNJS_Nac263FJMfFSQ54sIJwV9c_1lvyL3usH-mznqD05fkfoSWgUVQcp_sLucr9wryu6V5XRmVT77ftBX_BUCLWxU |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Novel+lncRNA-IUR+suppresses+Bcr-Abl-induced+tumorigenesis+through+regulation+of+STAT5-CD71+pathway&rft.jtitle=Molecular+cancer&rft.au=Xuefei+Wang&rft.au=Jianling+Yang&rft.au=Guijie+Guo&rft.au=Riyue+Feng&rft.date=2019-04-08&rft.pub=BMC&rft.eissn=1476-4598&rft.volume=18&rft.issue=1&rft.spage=1&rft.epage=15&rft_id=info:doi/10.1186%2Fs12943-019-1013-3&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_9daa59af618844a2b330c7c3ff1ed1b9 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon |